Findings reveal that a One-Strength dose-escalation regimen is safe and well-tolerated in individuals aged 5-65 years, indicating effective allergy treatment.
Birch pollen SCIT was safe and well-tolerated when administered using a One-Strength dose-escalation regimen in patients aged 5-65 years.
No takes yet. Share an insight, caveat, or question.
Jutel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: